Kelleher Financial Advisors Sells 8,560 Shares of Gilead Sciences, Inc. $GILD

Kelleher Financial Advisors lessened its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 49.7% during the third quarter, HoldingsChannel.com reports. The fund owned 8,654 shares of the biopharmaceutical company’s stock after selling 8,560 shares during the period. Kelleher Financial Advisors’ holdings in Gilead Sciences were worth $1,290,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. BlackRock Inc. bought a new position in Gilead Sciences in the 2nd quarter valued at $15,393,785,000. State Street Corp increased its holdings in shares of Gilead Sciences by 2.3% in the second quarter. State Street Corp now owns 61,216,552 shares of the biopharmaceutical company’s stock worth $7,734,099,000 after purchasing an additional 1,357,967 shares during the period. Amundi increased its holdings in shares of Gilead Sciences by 10.7% in the first quarter. Amundi now owns 10,539,111 shares of the biopharmaceutical company’s stock worth $1,468,836,000 after purchasing an additional 1,018,976 shares during the period. Legal & General Group Plc purchased a new stake in shares of Gilead Sciences in the second quarter worth $1,316,606,000. Finally, Deutsche Bank AG bought a new stake in Gilead Sciences during the second quarter valued at $918,387,000. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Stock Performance

NASDAQ GILD opened at $174.48 on Thursday. Gilead Sciences, Inc. has a 52-week low of $116.88 and a 52-week high of $175.65. The company has a fifty day moving average of $152.29 and a 200-day moving average of $140.52. The company has a market capitalization of $216.41 billion, a P/E ratio of -55.22 and a beta of 0.35. The company has a debt-to-equity ratio of 1.84, a quick ratio of 0.95 and a current ratio of 1.38.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, October 29th. The biopharmaceutical company reported $2.55 EPS for the quarter, beating analysts’ consensus estimates of $2.19 by $0.36. Gilead Sciences had a negative return on equity of 1.85% and a negative net margin of 12.47%. The business had revenue of $8.30 billion for the quarter, compared to analysts’ expectations of $7.81 billion. During the same quarter in the prior year, the firm earned $2.47 earnings per share. The firm’s revenue was up 6.8% on a year-over-year basis. As a group, equities research analysts predict that Gilead Sciences, Inc. will post -1.07 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 30th. Stockholders of record on Tuesday, December 15th will be paid a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a dividend yield of 1.9%. The ex-dividend date of this dividend is Tuesday, December 15th. Gilead Sciences’s dividend payout ratio (DPR) is -103.80%.

Insider Transactions at Gilead Sciences

In related news, Director Anthony Welters sold 18,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 26th. The stock was sold at an average price of $148.62, for a total transaction of $2,675,160.00. Following the transaction, the director directly owned 12,894 shares in the company, valued at $1,916,306.28. This trade represents a 58.26% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel O’Day sold 15,881 shares of Gilead Sciences stock in a transaction that occurred on Friday, October 30th. The stock was sold at an average price of $175.25, for a total value of $2,783,145.25. Following the completion of the transaction, the chief executive officer directly owned 566,683 shares in the company, valued at $99,311,195.75. This trade represents a 2.73% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 126,881 shares of company stock valued at $19,252,455. 0.30% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research firms recently commented on GILD. Needham & Company LLC set a $175.00 target price on Gilead Sciences in a research report on Friday, October 30th. Scotiabank raised their price target on Gilead Sciences from $177.00 to $200.00 and gave the company a “sector outperform” rating in a report on Friday, October 30th. Bank of America lifted their price target on Gilead Sciences from $168.00 to $172.00 and gave the company a “buy” rating in a research report on Tuesday, October 20th. TD Cowen boosted their price objective on Gilead Sciences from $160.00 to $175.00 and gave the stock a “buy” rating in a report on Friday, October 30th. Finally, Jefferies Financial Group set a $196.00 price objective on Gilead Sciences in a report on Wednesday. Twenty-three research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $170.15.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: DZ Bank raised its price target on Gilead to $191 from $167, signaling increased confidence in the stock’s prospects. DZ Bank Adjusts Price Target on Gilead Sciences to $191 From $167
• Positive Sentiment: Gilead and its Kite subsidiary plan 23 presentations, including seven oral presentations, at the December ASH meeting. The breadth of planned data across the pipeline and portfolio may draw investor attention to potential growth drivers. Gilead and Kite Advance Leadership With New Data Across Pipeline and Portfolio at ASH 2026
• Positive Sentiment: BioNTech and Gilead are advancing a global Phase 3 trial combining BioNTech’s pumitamig with Gilead’s cancer drug Trodelvy (sacituzumab govitecan) for metastatic triple-negative breast cancer. The collaboration expands the potential reach of Gilead’s oncology portfolio, though trial results remain to come. BioNTech Enters First Global Phase 3 Trial for New Breast Cancer Combo
• Neutral Sentiment: Gilead’s GS-1206 cancer study continues to advance, but investors are still waiting for early efficacy signals; the update did not provide results that establish the drug’s potential. Gilead’s GS-1206 Cancer Trial Advances as Investors Watch for Early Signals
• Negative Sentiment: Put-option purchases were unusually elevated, which may reflect increased hedging or bearish positioning, though options activity alone does not confirm a negative outlook.
• Negative Sentiment: CEO Daniel O’Day disclosed recent stock sales under a pre-arranged Rule 10b5-1 plan. The planned nature of the sales may limit their significance, but insider selling can still weigh on sentiment.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.